Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
about
A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD)The use of amisulpride in the treatment of acute psychosisRandomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternativesEthics of medication-free research in schizophrenia.The prevention and treatment of missing data in clinical trialsTransparent reporting of missing outcome data in clinical trials: applying the general principles of CONSORT 2010.Reporting and handling missing outcome data in mental health: a systematic review of Cochrane systematic reviews and meta-analyses.Statins in Primary Prevention: Uncertainties and Gaps in Randomized Trial Data.Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophreniaA systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia.Predictors of missed research appointments in a randomized placebo-controlled trial.Past and present progress in the pharmacologic treatment of schizophrenia.Use of the 'patient journey' model in the internet-based pre-fitting counseling of a person with hearing disability: lessons from a failed clinical trial.Attitudes toward Placebo-Controlled Clinical Trials of Patients with Schizophrenia in JapanAripiprazole: the evidence of its therapeutic impact in schizophreniaClinical Efficacy of Traditional Chinese Medicine, Suan Zao Ren Tang, for Sleep Disturbance during Methadone Maintenance: A Randomized, Double-Blind, Placebo-Controlled Trial.Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression.Patient and provider attitudes towards monitored naltrexone treatment of alcohol dependence in schizophrenia.Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study.Evidence review and clinical guidance for the use of ziprasidone in Canada.Maintaining Adherence Programme: evaluation of an innovative service modelFeasibility of reducing the duration of placebo-controlled trials in schizophrenia research.Improved in-hospital outcomes and care for patients in stroke research: An observational study.Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design featuresAdherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia.Second-generation antipsychotics for schizophrenia: can we resolve the conflict?Dose equivalents for second-generation antipsychotics: the minimum effective dose method.Sequential multiple assignment randomization trials with enrichment design.An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.The controversy of a wider statin utilization: why?Aripiprazole: a review of its use in the treatment of manic episodes in adolescents with bipolar I disorder.Methodological issues associated with preclinical drug development and increased placebo effects in schizophrenia clinical trials.Indirect comparison analysis of efficacy and safety between olanzapine and aripiprazole for schizophrenia.Patient recruitment for clinical trials on traditional Chinese medicine: Challenges, barriers, and strategies.Antipsychotic agents: efficacy and safety in schizophreniaGalantamine treatment in outpatients with mild Alzheimer's disease.Reducing impulsivity in repeat violent offenders: an open label trial of a selective serotonin reuptake inhibitor.
P2860
Q24624661-AD989F50-9DF4-4D5B-AB0F-515FB238F1D5Q24683055-492D518B-C4B7-4226-9773-CAEBC8B360F8Q26863435-E8A4538A-D6B9-4C06-92B7-E47EBF9C345BQ30440249-C797FB97-8BCE-4CB2-94C4-94DE0EAE2275Q30571921-EDF273AB-3937-4F44-9AAC-267F3CE515EFQ30811010-FD59B9CC-8E9D-4117-893B-061E2AE4FD8BQ30976019-7B62F384-9E54-482E-8723-851004102DEEQ31133434-4BC21A48-E543-47AC-BB06-07D764A4E8A4Q33814003-76E60956-53F2-4435-B9BA-D1D8C609501DQ34203368-21BBF390-93FC-4C32-A4A8-F00D1464F233Q34224372-C535A561-877E-4C29-8B59-D70CA1B52841Q34266750-3A1F07DB-F2B1-4A86-A132-E3335E94F651Q34475662-FCF78AC4-1EF0-432F-9963-B1463961A86FQ34726953-F847EF96-7337-472A-9BFD-B965AF459871Q35141189-EE881945-BA33-4E66-B701-FE9975E4D63AQ35850831-A232B9E7-C30E-44DA-A840-B86F12DEE369Q35876413-2ED0215D-BE1D-4659-BAA9-297C869763F5Q35964019-2D352C44-AE96-4BA2-A256-A89AA3D5CBB4Q36119267-32EEDD5C-ACC0-4B45-990D-6EF974C4194FQ36162037-FBE1F542-C345-477F-A19D-826D408CC02CQ36296259-0AE5FDAF-A3DA-4445-ACC8-E8D65BD55FB0Q36537114-FAF00299-0021-482B-AA44-41554C28982CQ36588607-B4563265-47A4-42FE-8543-6EF46A15A85BQ36623532-AC04A7E9-6F43-4C01-8914-EB35BC01371AQ37076279-B0E0BCD7-C349-474D-A978-6F0865D2965EQ37082961-D78E3893-6AE2-45C9-90D2-36D0C80CA251Q37227479-0B6CCCB3-002B-44C9-AD5C-772AC8F75411Q37405519-2F370696-CE3B-446F-A2FA-956D4F330D0DQ37428125-B420F7C2-5AFC-442C-8FCB-88AAFCB1E06FQ37598284-8F2F5DDD-AD1D-4EF5-A3F5-F9662EBB20F8Q37682974-7436D3DB-2D4B-457A-9B51-058CF1358754Q38051283-21A6DE6E-D1F0-47AD-8F83-44ED367ACB2FQ38089090-93FC9FC0-B023-4883-AFCD-2581556D7E67Q38176566-E70FEDE4-8CD2-4EBB-A998-E3E0E5F1D2A3Q38676860-02271937-5228-4D2B-BF0F-F777C5091C7DQ39051449-6790D6A2-3C73-49F7-B4B0-688ED21B34FCQ41847324-ED66B541-7A9A-4B9B-9BC5-FC4930C44661Q41957512-F61C0D9D-09C3-4946-BB38-1F3D26835126Q42639500-B2E04371-28FC-4596-A7C5-F74A5E4685BDQ42681553-5F30BA34-DEFD-42E2-95F8-279EE5750978
P2860
Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Dropout rates in placebo-contr ...... chotic drugs: a meta-analysis.
@en
Dropout rates in placebo-contr ...... chotic drugs: a meta-analysis.
@nl
type
label
Dropout rates in placebo-contr ...... chotic drugs: a meta-analysis.
@en
Dropout rates in placebo-contr ...... chotic drugs: a meta-analysis.
@nl
prefLabel
Dropout rates in placebo-contr ...... chotic drugs: a meta-analysis.
@en
Dropout rates in placebo-contr ...... chotic drugs: a meta-analysis.
@nl
P2093
P1433
P1476
Dropout rates in placebo-contr ...... chotic drugs: a meta-analysis.
@en
P2093
Christian Widschwendter
Georg Kemmler
Martina Hummer
W Wolfgang Fleischhacker
P304
P356
10.1001/ARCHPSYC.62.12.1305
P407
P577
2005-12-01T00:00:00Z